Press "Enter" to skip to content

Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy – Endpoints News

admin 0

Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy  Endpoints News

AstraZeneca’s big bet on a combination of its checkpoint inhibitor Imfinzi and in-house CTLA-4 drug has proved exceedingly costly, but the British drugmaker …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *